Zydus Lifesciences Ltd Q4FY25; 0% fall in Profits

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Financial Results:

Zydus Lifesciences Ltd reported Revenues for Q4FY25 of ₹6,528.00 Crores up from ₹5,534.00 Crore year on year, a rise of 17.96%.

Total Expenses for Q4FY25 of ₹4,717.00 Crores up from ₹4,143.00 Crores year on year, a rise of 13.85%.

Consolidated Net Profit of ₹1,244.00 Crores down 0.16% from ₹1,246.00 Crores in the same quarter of the previous year.

The Earnings per Share is ₹11.64, down 0.94% from ₹11.75 in the same quarter of the previous year.